In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MediGene Inc.

Division of Medigene AG
www.medigene.de

Latest From MediGene Inc.

Asia Deal Watch: Antibody-Drug Conjugates Reign With Alliances Involving Celltrion, Miracogen & WuXi Biologics

Celltrion and iProgen will co-develop ADC candidates, Miracogen and Synaffix sign a technology license after a successful research collaboration, and WuXi will provide clinical trial material to NBE Therapeutics.

Deals Commercial

A Question Of Identity: Drug & Botanical Perspectives On Manufacturing Clash In Fulyzaq Review

Salix’ botanical product Fulyzaq tested the limits of the conventional small molecule chemistry approach to ensuring the identity of drug substance. After a regulatory briefing with CDER Director Woodcock, the botanicals and CMC review teams agreed on a bioassay to bridge the gap in their regulatory perspectives.

BioPharmaceutical Manufacturing

Chinese Drug Firms Race To U.S. With Traditional Medicines

Luye Pharma is the latest Chinese domestic drug manufacturer aiming to launch prescription traditional Chinese medicines in the U.S.

BioPharmaceutical China

Germany's Growth Story

Germany's biotech investment has propelled a handful of companies onto the public markets a lot sooner than their US or UK counterparts. These German companies have followed aggressive acquisition strategies, most often buying into the US, sometimes using newly-minted Neuer Markt paper. Some are seeking through these acquisitions to both broaden their technology platform and acquire a product portfolio, hoping thereby to avoid the pitfalls of a narrow focus. It's too early to tell whether such a dual model will work. But the fact that Germany's young companies are finding their own approach to competing globally shows that the country's biotech initiative has already had some success.
BioPharmaceutical Europe
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • NeuroVir Therapeutics Inc.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Medigene AG
  • Senior Management
  • Contact Info
  • MediGene Inc.
    Phone: (858) 586-2240
    10650 Scripps Ranch Blvd.
    Ste. 230
    San Diego, CA 92131
    USA
UsernamePublicRestriction

Register